Reuters -- Nycomed, the private equity-owned Swiss drugmaker, is looking at sweetening its bid for Solvay’s drugs unit with the Belgian chemical and drug maker’s board set to meet to decide on the unit’s future.
Reuters -- Nycomed, the private equity-owned Swiss drugmaker, is looking at sweetening its bid for Solvay’s drugs unit with the Belgian chemical and drug maker’s board set to meet to decide on the unit’s future.
